A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP.
Publication Title
Cancer Med
Document Type
Article
Publication Date
4-1-2025
Keywords
Humans; Sentinel Lymph Node Biopsy; Melanoma; Female; Male; Middle Aged; Prospective Studies; Skin Neoplasms; Aged; Neoplasm Recurrence, Local; Adult; Gene Expression Profiling; Disease-Free Survival; Aged, 80 and over; Transcriptome; Melanoma, Cutaneous Malignant; Sentinel Lymph Node; california; santa monica; psjci
Abstract
BACKGROUND: Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%-30% of these patients will recur. The 31-gene expression profile (31-GEP) test has been prospectively validated to identify patients at low (Class 1A), intermediate (Class 1B/2A), and high (Class 2B) risk of SLN positivity and recurrence.
METHODS: DECIDE is a prospective, multicenter study to assess the effect of 31-GEP testing on SLNB performance rates in patients with T1-T2 tumors considering SLNB and to study long-term outcomes. Here, we assessed outcomes in patients with a Class 1A 31-GEP result (n = 130).
RESULTS: Of Class 1A patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up).
CONCLUSIONS: These results are consistent with previous studies that showed the 31-GEP can identify patients at low risk of SLN positivity and recurrence.
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
DOI
10.1002/cam4.70839
